ERBB2 and breast cancer: The objective of this study was therefore to understand how patients’ preferences for characteristics of postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of treatment with letrozole or anastrozole and to estimate their willingness-to-pay (WTP) by using a discrete choice experiment (DCE).